Aptevo Therapeutics Inc. - 8-K Filing

Aptevo Therapeutics reports 21% of frontline AML patients treated with mipletamig triplet advanced to stem cell transplant (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

3 articles from 1 source · updated October 26, 2026, 20:05 UTC

Coverage

• Acrivon Therapeutics, Inc. - 4 Filing SEC EDGAR · October 26, 2026, 20:04 UTC
• Oncotelic Therapeutics, Inc. - 8-K Filing SEC EDGAR · October 26, 2026, 13:00 UTC
• Aptevo Therapeutics Inc. - 8-K Filing SEC EDGAR · October 26, 2026, 12:14 UTC